The Methylation Analysis of KLF11 and PCDH9 Genes in Patients with Non-Small Cell Lung Cancer

S. Nooshin, S. Z. Karizi, M. Karimipoor, Maryam Nooshin, A. Ahmadi, Maryam Changizi maghroor, Masoumeh Masrouri
{"title":"The Methylation Analysis of KLF11 and PCDH9 Genes in Patients with Non-Small Cell Lung Cancer","authors":"S. Nooshin, S. Z. Karizi, M. Karimipoor, Maryam Nooshin, A. Ahmadi, Maryam Changizi maghroor, Masoumeh Masrouri","doi":"10.5539/CCO.V7N1P47","DOIUrl":null,"url":null,"abstract":"Background: Lung cancer is the leading cause of cancer-related deaths worldwide and the 5-year survival rate is still very poor due to the lack of effective tools for early detection. Epigenetics and especially studies on DNA methylation have given important information towards a better achievement of lung cancer pathogenesis in the recent decades. The inactivation of tumor suppressor genes via promoter hypermethylation is an obvious mechanism and is straightly related to carcinogenesis. In this study, we compared the methylation status of KLF11 and PCDH9 genes in non-small cell lung cancer and adjacent normal tissues.Methods: Genomic DNA was extracted from 30 tumor tissues, bisulfite treated and were analyzed in terms of promoter methylation status of KLF11 and PCDH9 genes by high resolution melting method. Statistical analysis was carried out by chi-square test.Results: No significant difference in methylation level at the PCDH9 promoter region in NSCLC tumors compared with non-tumor tissues was observed (P = 0.3132, chi-square test). In contrast, the difference in methylation levels between normal and tumor tissue samples for the promoter of the KLF11 gene was quite significant (P = 0.0001).Conclusions: Promoter methylation of KLF11 gene is an important mechanism in the development of NSCLC, therefore, it could be used as one of the potential therapeutic goals for molecular targeted therapy and epigenetic treatment. The role of the PCDH9 gene in the development of lung cancer is complex and requires more research and a larger statistical population.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"7 1","pages":"47"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V7N1P47","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5539/CCO.V7N1P47","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Background: Lung cancer is the leading cause of cancer-related deaths worldwide and the 5-year survival rate is still very poor due to the lack of effective tools for early detection. Epigenetics and especially studies on DNA methylation have given important information towards a better achievement of lung cancer pathogenesis in the recent decades. The inactivation of tumor suppressor genes via promoter hypermethylation is an obvious mechanism and is straightly related to carcinogenesis. In this study, we compared the methylation status of KLF11 and PCDH9 genes in non-small cell lung cancer and adjacent normal tissues.Methods: Genomic DNA was extracted from 30 tumor tissues, bisulfite treated and were analyzed in terms of promoter methylation status of KLF11 and PCDH9 genes by high resolution melting method. Statistical analysis was carried out by chi-square test.Results: No significant difference in methylation level at the PCDH9 promoter region in NSCLC tumors compared with non-tumor tissues was observed (P = 0.3132, chi-square test). In contrast, the difference in methylation levels between normal and tumor tissue samples for the promoter of the KLF11 gene was quite significant (P = 0.0001).Conclusions: Promoter methylation of KLF11 gene is an important mechanism in the development of NSCLC, therefore, it could be used as one of the potential therapeutic goals for molecular targeted therapy and epigenetic treatment. The role of the PCDH9 gene in the development of lung cancer is complex and requires more research and a larger statistical population.
非小细胞肺癌患者KLF11和PCDH9基因的甲基化分析
背景:癌症是全球癌症相关死亡的主要原因,由于缺乏有效的早期检测工具,5年生存率仍然很低。近几十年来,表观遗传学特别是DNA甲基化的研究为更好地研究癌症的发病机制提供了重要信息。抑癌基因通过启动子超甲基化失活是一个明显的机制,与致癌直接相关。在本研究中,我们比较了非小细胞肺癌癌症和邻近正常组织中KLF11和PCDH9基因的甲基化状态。方法:从30个亚硫酸氢盐处理的肿瘤组织中提取基因组DNA,并用高分辨率熔解法分析KLF11和PCDH9基因的启动子甲基化状态。采用卡方检验进行统计分析。结果:与非肿瘤组织相比,NSCLC肿瘤中PCDH9启动子区的甲基化水平没有显著差异(P=0.3132,卡方检验)。结论:KLF11基因启动子甲基化是NSCLC发生发展的重要机制,可作为分子靶向治疗和表观遗传学治疗的潜在治疗目标之一。PCDH9基因在癌症发展中的作用是复杂的,需要更多的研究和更大的统计群体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书